Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03697564
Title Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial).
Recruitment Suspended
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Hitendra Patel
Indications

pancreatic adenocarcinoma

Therapies

Cabiralizumab + Gemcitabine + Nivolumab

Gemcitabine

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.